DATA GRAPHICS | Product Development Retatrutide data strengthen Lillys hand in high-BMI obesity Phase III data put weight loss above CagriSemas benchmark, with tolerability that may be good enough to preserve a commercial edge May 21, 2026 7:09 PM UTC Lilly again has the frontrunner in the weight loss Olympics: its triple agonist retatrutide showed greater Phase III obesity efficacy than Novo Nordisks dual-acting CagriSema, with a tolerability profile that does not appear markedly worse
It is a structurally modified 39-amino-acid peptide engineered for once-weekly subcutaneous delivery in clinical trials
Reagent A contains components for both color reaction and deproteination
Interest in injectable peptides is rising as more people see them promoted online through health and wellness influencers for weight loss, muscle growth, recovery and anti-aging
Green Tea Extract Green tea extract contains natural caffeine which may increase energy levels temporarily and help the body to burn off more fat
Read on to learn more about the dangers of obtaining Reta from the grey market and how clinicians can help patients navigate this growing concern
